Freenome
its SimpleScreen colorectal-cancer blood test met all primary and secondary endpoints (85% sensitivity for CRC, 22% for advanced precancerous lesions), alongside separate multiomic lung-cancer screening data.
- Country
- United States
Growth
SimpleScreen CRC / lung multiomic screen
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-cancer early detection (MCED) | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.